A

AGILENT TECHNOLOGIES INC

Healthcare • USA

Apr 05 • 04:00PM ET
113.77
+1.37 (+1.22%)
Company Profile

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave ... read more

Full Time Employees 17,400
Phone 800 227 9770
Website https://www.agilent.com
CEO Mr. Padraig McDonnell
IPO Date 1999-11-18
Sector Healthcare
Industry Medical - Diagnostics & Research
Address 5301 Stevens Creek Boulevard, Santa Clara, CA 95051
Balance Sheet
Total Cash $1,467,000,000
Total Debt $3,363,000,000
Current Ratio 2.20
Quick Ratio 1.50
Profitability
Gross Margin 53.97%
Net Margin 19.27%
ROE 20.89%
ROA 10.57%
ROIC 13.36%
Balance Sheet
Total Cash $1,467,000,000
Total Debt $3,363,000,000
Current Ratio 2.20
Quick Ratio 1.50
Profitability
Gross Margin 53.97%
Net Margin 19.27%
ROE 20.89%
ROA 10.57%
ROIC 13.36%
Name AGILENT TECHNOLOGIES INC Sector Healthcare Currency USD Relative Volume 1.94 Market Cap 29365
Current Ratio 2.2 Dividend / Share 0.956 EPS 4.36 Revenue 6533000000 P/S 4.5
P/E 23.3 Beta 0.88 Income 1259000000 Volume 3824454 Average Volume 1970138
Distance to 200DMA -24.05% 200 DMA 135.62 50 DMA 130.69 ROA 11.0 ROE 20.9
Distance to 50DMA -21.19% Return 1Y -27.96% Return YTD -23.33% Forward PE Qtly Growth YOY
Debt/Eq 0.98 P/B 4.9 Dividend Yield 0.6% Net Margin 19.27% Payout Ratio 21.9
Performance
52 Week Range 21.9%
Distance to 200DMA 0.21%
Day Change Percent $0.24
Performance Week $0.236
Performance Month $0.236
Performance Quarter 2024-07-02
Performance YTD $0.236
Performance Year $0.236

Performance Range

Day

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Month

$196
Current
Low: High:
Balance Sheet
Total Cash $1,779,000,000
Total Debt $2,932,000,000
Current Ratio 1.78%
Quick Ratio 1.26%
Profitability
Gross Margin 53.97%
Net Margin 19.27%
ROE 20.89%
ROA 10.57%
ROIC 13.36%
Valuation
Price to Earnings 25.75
Price to Book 5.38
Price to Sales 4.96
Price to Free Cash Flow 24.71
Dividends
Payout Ratio 21.64%
Dividend Yield 0.84%
Dividend Amount $0.24
Last Dividend Pay Date 2024-07-02
Last Dividend Paid $0.236
Performance
52 Week Range 21.9%
Distance to 200DMA 0.21%
Day Change Percent $0.24
Performance Week $0.236
Performance Month $0.236
Performance Quarter 2024-07-02
Performance YTD $0.236
Performance Year $0.236
Company Profile

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave ... read more

Full Time Employees 17,400
Phone 800 227 9770
Website https://www.agilent.com
CEO Mr. Padraig McDonnell
IPO Date 1999-11-18
Sector Healthcare
Address 5301 Stevens Creek Boulevard, Santa Clara, CA 95051
Histogram - Daily

Balance Sheet
Total Cash $1,779,000,000
Total Debt $2,932,000,000
Current Ratio 1.78%
Quick Ratio 1.26%
Profitability
Gross Margin 0.5440%
Net Margin 0.2170%
ROE 0.23%
ROA 0.13%
Company Profile

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave ... read more

Full Time Employees 17,400
Phone 800 227 9770
Website https://www.agilent.com
CEO Mr. Padraig McDonnell
IPO Date 1999-11-18
Sector Healthcare
Address 5301 Stevens Creek Boulevard, Santa Clara, CA 95051
Monthly Win Rate

Balance Sheet (Multi-Column Example)
Dec 2024 Sep 2024 Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023 Mar 2023
Cash & Short Term Investments 53,775.0 65,171.0 61,801.0 67,150.0 73,100.0 61,555.0 62,482.0 55,872.0
Receivables 59,306.0 66,243.0 43,172.0 41,150.0 50,102.0 60,985.0 39,186.0 35,899.0
Inventory 6,911.0 7,286.0 6,165.0 6,232.0 6,511.0 6,331.0 7,351.0 7,482.0

Latest News

Agilent to Participate in Jefferies Global Healthcare Conference
Agilent to Participate in Jefferies Global Healthcare Conference

SANTA CLARA, Calif--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell — along with CFO Bob McMahon — will participate in a fireside chat at the Jefferies

2025-05-15 16:14:00 - businesswire.com
Scale Has Its Advantages: 3 A-Rated REIT Monopolies
Scale Has Its Advantages: 3 A-Rated REIT Monopolies

Scale is a critical competitive advantage for companies, enabling them to expand, attract capital, and achieve strong market positions, as seen with Realty Income, Prologis, and Public Storage. Realty

2025-05-10 07:00:00 - seekingalpha.com
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

2025-04-29 09:56:14 - zacks.com
City Office REIT (RED PFD SER A): A High Yield, Deep Value Opportunity Worth Latching Onto
City Office REIT (RED PFD SER A): A High Yield, Deep Value Opportunity Worth Lat

City Office REIT's Series A Preferred Shares offer a tempting yield despite recent accounting losses and systemic pressures, suggesting a potential buying opportunity. The shares are cumulative, redee

2025-04-24 09:52:15 - seekingalpha.com
Agilent Receives European IVDR Certification for Companion Diagnostic Assay in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Agilent Receives European IVDR Certification for Companion Diagnostic Assay in G

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Compan

2025-04-17 08:00:00 - businesswire.com
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Na

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

2025-04-11 09:55:39 - zacks.com
Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval
Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics' FDA approval for AUCATZYL®, a recently approved CAR T ther

2025-03-24 08:00:00 - businesswire.com
Agilent Research Catalyst Award Presented to Columbia University for Professor Pawel Muranski
Agilent Research Catalyst Award Presented to Columbia University for Professor P

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Columbia University has received an Agilent Research Catalyst (ARC) Award on behalf of Dr. Pawel Muranski

2025-03-19 08:00:00 - businesswire.com
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Dia

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU IVDR1,

2025-03-10 08:19:00 - businesswire.com
Agilent Technologies, Inc. (A) TD Cowen 45th Annual Healthcare Conference (Transcript)
Agilent Technologies, Inc. (A) TD Cowen 45th Annual Healthcare Conference (Trans

Agilent Technologies, Inc. (NYSE:A ) TD Cowen 45th Annual Healthcare Conference Call March 4, 2025 9:50 AM ET Company Participants Padraig McDonnell - Chief Executive Officer Bob McMahon - Chief Finan

2025-03-04 15:55:36 - seekingalpha.com
Agilent Technologies (A) Q1 Earnings and Revenues Beat Estimates
Agilent Technologies (A) Q1 Earnings and Revenues Beat Estimates

Agilent Technologies (A) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.29 per share a year ago.

2025-02-26 18:16:11 - zacks.com
Agilent to Report Q1 Earnings: What's in the Cards for the Stock?
Agilent to Report Q1 Earnings: What's in the Cards for the Stock?

A's fiscal first-quarter performance is likely to have been influenced by higher expenses, increased CapEx and the Lunar New Year timing shift.

2025-02-24 14:30:27 - zacks.com